Thoracic duct

WhiteSwell Announces Six-month Outcomes After eLym System Treatment for Acute Decompensated Heart Failure Patients in its DELTA-HF Study

Retrieved on: 
Mercoledì, Marzo 6, 2024
Medical Devices, Health, Surgery, Clinical Trials, Cardiology, Biotechnology, Peripheral edema, Thoracic duct, Acute decompensated heart failure, Ohio State University, Physiology, Drainage, Congestion, Heart failure, ADHF, Cell biology, Death, Patient, Lymphatic system, Medicine, THT, Tissue, Pharmaceutical industry

WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive six-month follow-up data on the initial nine patients treated in its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.

Key Points: 
  • WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive six-month follow-up data on the initial nine patients treated in its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.
  • Nine hospitalized patients with ADHF received eLym therapy in conjunction with diuretic therapy and were followed for six months.
  • Reduced rehospitalizations: Comparing patients’ clinical course before and after eLym therapy, in the six months prior to eLym therapy there were 13 heart failure related hospitalizations, while in the six months after eLym therapy there were just two heart failure hospitalizations and one heart failure related death, for a 77% reduction.
  • The minimally invasive catheter system was successfully deployed and removed in all patients, with a mean treatment time of 24 hours.

WhiteSwell Announces Successful Treatment of Acute Decompensated Heart Failure Patients in its Early Feasibility DELTA-HF Study

Retrieved on: 
Sabato, Ottobre 7, 2023
Health, Clinical Trials, Cardiology, Medical Devices, ADHF, Heart Failure Society of America, Lymphatic system, Acute decompensated heart failure, Feasibility, Risk, ICCU, Creatinine, Ohio State University Wexner Medical Center, Cell biology, Congestion, Ohio State University, Thoracic duct, Kidney, Heart failure, Safety, Patient, Tissue, Drainage, Pharmaceutical industry, Medical imaging, Physiology

WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive initial results from its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.

Key Points: 
  • WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive initial results from its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.
  • The data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023 in Cleveland, Ohio.
  • Nine hospitalized patients received eLym therapy in conjunction with diuretic therapy, while six patients received standard of care treatment with loop diuretics alone.
  • “It cannot be overemphasized how significant and challenging it is to fully decongest patients hospitalized with decompensated heart failure.

BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease

Retrieved on: 
Venerdì, Dicembre 3, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, PARP, Overalls, Company, NMPA, Siltuximab, Bristol Myers Squibb, Medication package insert, Effectiveness, Idiopathic multicentric Castleman disease, EU, Neoplasm, Diarrhea, Jazz Pharmaceuticals, Marketing, Global health, Tislelizumab, MCD, HIV, Private Securities Litigation Reform Act, Approved, Product, Anaphylaxis, Lymphoma, General manager, Research, Arthralgia, Itch, Respiratory tract, Review, Infection, Rash, EUSA, Therapy, Goal, U.S. Securities and Exchange Commission, Intellectual property, BTK, Twitter, Adult, NASDAQ, Lymph, FDA, Multimedia, HHV-8, Patient, Tissue, National Medical Products Administration, Safety, Technology, Novartis, IL-6, Degenerative disease, Thoracic duct, COVID-19, EMA, Union, Disease, Vaccine, Pharmaceutical industry, SYLVANT® (siltuximab for injection), EUSA Pharma, BeiGene, SYLVANT® (SILTUXIMAB FOR INJECTION), EUSA PHARMA, BEIGENE

Siltuximab is a monoclonal antibody approved in the United States, European Union, and other countries and regions around the world.

Key Points: 
  • Siltuximab is a monoclonal antibody approved in the United States, European Union, and other countries and regions around the world.
  • This approval is our second product in our collaboration with EUSA, highlighting the combined expertise of our companies as we work together on behalf of patients.
  • Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease.
  • We commercialize a range of oncology medicines in China licensed from Amgen, Bristol Myers Squibb, EUSA Pharma, and Bio-Thera.

BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease

Retrieved on: 
Venerdì, Dicembre 3, 2021
Science, Biotechnology, Research, Pharmaceutical, Physical Therapy, Health, Infectious Diseases, Clinical Trials, PARP, Overalls, Company, NMPA, Siltuximab, Bristol Myers Squibb, Medication package insert, Effectiveness, Idiopathic multicentric Castleman disease, EU, Neoplasm, Diarrhea, Jazz Pharmaceuticals, Marketing, Global health, Tislelizumab, MCD, HIV, Private Securities Litigation Reform Act, Approved, Product, Anaphylaxis, Lymphoma, General manager, Research, Arthralgia, Itch, Respiratory tract, Review, Infection, Rash, EUSA, Therapy, Goal, U.S. Securities and Exchange Commission, Intellectual property, BTK, Twitter, Adult, NASDAQ, Lymph, FDA, HHV-8, Patient, Tissue, National Medical Products Administration, Safety, Technology, Novartis, IL-6, Degenerative disease, Thoracic duct, COVID-19, EMA, Union, Disease, Vaccine, Pharmaceutical industry

Todays approval provides a new treatment for patients in China with this rare systemic disorder, commented Xiaobin Wu, Ph.D., President, Chief Operating Officer, and General Manager of China at BeiGene.

Key Points: 
  • Todays approval provides a new treatment for patients in China with this rare systemic disorder, commented Xiaobin Wu, Ph.D., President, Chief Operating Officer, and General Manager of China at BeiGene.
  • This approval is our second product in our collaboration with EUSA, highlighting the combined expertise of our companies as we work together on behalf of patients.
  • Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease.
  • We commercialize a range of oncology medicines in China licensed from Amgen, Bristol Myers Squibb, EUSA Pharma, and Bio-Thera.